{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Colon&page=5",
    "query": {
      "condition": "Cancer Colon",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 3053,
    "total_pages": 306,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Colon&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Colon&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T10:52:02.793Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05167409",
      "title": "Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Microsatellite Stable Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Evorpacept (ALX148)",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2022-07-28",
      "completion_date": "2024-10-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 4,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • New Brunswick, New Jersey + 1 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05167409"
    },
    {
      "nct_id": "NCT00897793",
      "title": "Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Lung Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "venipuncture",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-01",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-04-12",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897793"
    },
    {
      "nct_id": "NCT05732233",
      "title": "RITUAL Ultivision AI CADe Randomized Controlled Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colon Adenoma",
        "Polyp of Colon",
        "Adenoma Colon"
      ],
      "interventions": [
        {
          "name": "Ultivision AI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Satisfai Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 137,
      "start_date": "2023-07-21",
      "completion_date": "2024-02-23",
      "has_results": false,
      "last_update_posted_date": "2024-05-13",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Kansas City, Kansas",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05732233"
    },
    {
      "nct_id": "NCT04191655",
      "title": "High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Inflammatory Bowel Diseases",
        "Colon Dysplasia",
        "Ulcerative Colitis",
        "Crohn Colitis",
        "Indeterminate Colitis"
      ],
      "interventions": [
        {
          "name": "High Definition Colonoscopy",
          "type": "DEVICE"
        },
        {
          "name": "Dye Spraying Chromocolonoscopy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2019-04-03",
      "completion_date": "2024-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Burlington, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Burlington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04191655"
    },
    {
      "nct_id": "NCT06133439",
      "title": "Rural Indiana Screening for Colorectal Cancer",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Colorectal Screen rates with implementation of evidence-based intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2023-01-03",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 1,
      "location_summary": "Monroe, Indiana",
      "locations": [
        {
          "city": "Monroe",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06133439"
    },
    {
      "nct_id": "NCT00005877",
      "title": "Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "rubitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "1999-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 1,
      "location_summary": "Dublin, California",
      "locations": [
        {
          "city": "Dublin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005877"
    },
    {
      "nct_id": "NCT00020267",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Adult Soft Tissue Sarcoma",
        "Colorectal Cancer",
        "Bone Cancer",
        "Ovarian Sarcoma",
        "Melanoma",
        "Colon Cancer",
        "Rectal Cancer",
        "Breast Cancer",
        "Eye Cancer",
        "Uterine Sarcoma"
      ],
      "interventions": [
        {
          "name": "interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "MAGE-12 peptide vaccine",
          "type": "DRUG"
        },
        {
          "name": "Montanide ISA-51",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020267"
    },
    {
      "nct_id": "NCT00532909",
      "title": "Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anal, Colon, and Rectal Cancers",
        "Colorectal Neoplasms",
        "Colon/Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Vandetanib",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Branimir Sikic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2006-07",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2012-07-16",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00532909"
    },
    {
      "nct_id": "NCT00831571",
      "title": "Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Small Bowel Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2009-02",
      "completion_date": "2022-04",
      "has_results": false,
      "last_update_posted_date": "2022-04-18",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00831571"
    },
    {
      "nct_id": "NCT00449163",
      "title": "Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Floxuridine",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 25,
      "start_date": "2006-03-01",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-11",
      "last_synced_at": "2026-10-21T10:52:02.793Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00449163"
    }
  ]
}